BeOne Medicines: Owning The Full B-Cell Treatment Sequence

BeOne Medicines is transitioning from a BRUKINSA-driven story to an integrated hematology and oncology platform with multiple growth drivers. Q1 2026 results show 35.5% revenue growth, expanding margins, and rising profitability, supporting a premium valuation justified by strong operational leverage. BRUKINSA, BEQALZI, and tacabrutideg form a defensible three-asset hematology moat, while a solid-tumor pipeline and manufacturing expansion drive future diversification. Despite high concentration risk and a demanding valuation, ONC’s evolving product ecosystem and cash flow generation underpin a bullish outlook.

I have a favorable outlook on BeOne Medicines (ONC) because it is moving from a BRUKINSA growth story to an integrated hematology franchise that offers multiple opportunities to treat B-cell cancers throughout their treatment.